Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,144,189
  • Shares Outstanding, K 161,974
  • Annual Sales, $ 705,140 K
  • Annual Income, $ -453,900 K
  • EBIT $ -278 M
  • EBITDA $ -287 M
  • 60-Month Beta 0.29
  • Price/Sales 13.92
  • Price/Cash Flow N/A
  • Price/Book 21.27

Options Overview Details

View History
  • Implied Volatility 46.57% (+5.31%)
  • Historical Volatility 29.60%
  • IV Percentile 36%
  • IV Rank 20.95%
  • IV High 86.76% on 04/09/25
  • IV Low 35.92% on 09/08/25
  • Expected Move (DTE 18) 4.75 (5.89%)
  • Put/Call Vol Ratio 3.56
  • Today's Volume 123
  • Volume Avg (30-Day) 874
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 29,472
  • Open Int (30-Day) 30,089
  • Expected Range 75.89 to 85.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.78
  • Number of Estimates 6
  • High Estimate -0.39
  • Low Estimate -1.02
  • Prior Year -0.93
  • Growth Rate Est. (year over year) +16.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.92 +3.28%
on 02/26/26
86.74 -6.03%
on 02/05/26
-1.56 (-1.88%)
since 02/02/26
3-Month
74.20 +9.85%
on 01/20/26
86.74 -6.03%
on 02/05/26
+0.20 (+0.25%)
since 12/02/25
52-Week
23.95 +240.33%
on 04/09/25
86.74 -6.03%
on 02/05/26
+48.32 (+145.59%)
since 02/28/25

Most Recent Stories

More News
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including...

IONS : 81.85 (+0.86%)
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

– PDUFA date set for June 30, 2026 –

IONS : 81.85 (+0.86%)
Ionis Pharmaceuticals: Q4 Earnings Snapshot

Ionis Pharmaceuticals: Q4 Earnings Snapshot

IONS : 81.85 (+0.86%)
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

- TRYNGOLZA ® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track,...

IONS : 81.85 (+0.86%)
Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36 ...

IONS : 81.85 (+0.86%)
Ionis updates time for fourth quarter and full year 2025 financial results webcast

Webcast scheduled for Wednesday, February 25 at 8:30 a.m. Eastern Time

IONS : 81.85 (+0.86%)
Ionis to hold fourth quarter and full year 2025 financial results webcast

Webcast scheduled for Wednesday, February 25 at 11:30 a.m. Eastern Time

IONS : 81.85 (+0.86%)
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose...

IONS : 81.85 (+0.86%)
BIIB : 187.22 (-2.40%)
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA™ (donidalorsen) in the European...

IONS : 81.85 (+0.86%)
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA 1 Biogen...

IONS : 81.85 (+0.86%)
BIIB : 187.22 (-2.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

See More

Key Turning Points

3rd Resistance Point 84.19
2nd Resistance Point 83.14
1st Resistance Point 82.15
Last Price 81.85
1st Support Level 80.11
2nd Support Level 79.06
3rd Support Level 78.07

See More

52-Week High 86.74
Last Price 81.85
Fibonacci 61.8% 62.75
Fibonacci 50% 55.35
Fibonacci 38.2% 47.94
52-Week Low 23.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar